Currently more than 70 biosimilar monoclonal antibodies (MAbs) are under development, and multiple originator MAbs are going off patent in the next three to four years. Protein A affinity media material remains the most important workhorse for the purification of monoclonal antibodies.
Photo 1: Amsphere A3 is a new protein A resin designed with a surfacemodified base bead and alkali-resistant optimized ligand.
Protein A media has a high impact on both development and manufacturing costs, particularly during early stage clinical phases. This note summarizes key performance parameters for JSR Life Science’s Amsphere A3 high-capacity protein A resin for six biosimilar molecules of which five are MAbs, and one is a Fc-fusion protein.